CCM
VIGL

CAAS Capital Management’s Vigil Neuroscience VIGL Stock Holding History

CAAS Capital Management’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-75,000
Closed -$527K – 1037
2022
Q1 		$527K Buy
+75,000
New +$990K 0.02% 381

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

CAAS Capital Management's VIGL Position: Q2 2022 in Review

CAAS Capital Management sold out of Vigil Neuroscience (VIGL) in Q2 2022, closing a stake of 75,000 shares — an estimated $527K sold.

CAAS Capital Management first reported a position in VIGL in Q1 2022 and held it in 1 quarter. The position peaked at $527K in Q1 2022. 35 funds tracked by Wall St. Rank hold VIGL as of Q2 2022.

  • CAAS Capital Management reported no remaining Vigil Neuroscience position as of Q2 2022 after selling out during the quarter.
  • CAAS Capital Management sold 75,000 Vigil Neuroscience shares in Q2 2022, an estimated $527K.
  • CAAS Capital Management first reported a position in Vigil Neuroscience in Q1 2022 and held it in 1 quarter.
  • CAAS Capital Management's Vigil Neuroscience position peaked at $527K in Q1 2022.
  • 35 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2022.

Based on CAAS Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.